DexCom, Inc. (DXCM) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YClears the 15%+ revenue bar over 10Y.
- Score
- 57/100
- 10Y CAGR
- 27.8%
- Median YoY
- 24.6%
- YoY volatility
- σ 12.0pp· uneven
- Quarters ≥ 20%
- 28 of 40
- Negative quarters
- 0
- Valuation vs own 10Y history
- P/S 7.1x · 10Y median 12.6x · 13th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 28 of 40 → 28 of 40 pts
- Steadiness (typical swing 12.0pp) → 16.4 of 25 pts
- Pace (median 24.6% YoY) → 12.8 of 20 pts
- Latest quarter (13.1% YoY) → 0 of 15 pts
- Score: 57 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 27.8% | 24.6% | 12.0pp | 28 of 40 | 0 |
| EPSEPS | — | — | — | — | — |
| Op cash flowOperating cash flow | 40.2% | 31.6% | 229.8pp | 22 of 38 | 10 |
| EBITDAEBITDA | — | 41.3% | 178.8pp | 21 of 28 | 4 |
| FCFFree cash flow | 52.6% | 34.3% | 272.1pp | 16 of 30 | 10 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: DXCM on the compounders surface · All compounders, ranked